Juan Carlos Velez, MD
Nephrology · New Orleans, LANPI 1982712840
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (55.6%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. Mallinckrodt Hospital Products Inc. accounts for 76.3% of it on its own, with 16 other manufacturers making up the rest. Among nephrology clinicians in LA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 183 payments — averaging $1541.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Mallinckrodt Hospital Products Inc.$215K
- Travere Therapeutics, Inc.$20K
- Otsuka America Pharmaceutical, Inc.$19K
- Calliditas Therapeutics US Inc.$12K
- Mallinckrodt Enterprises LLC$11K
- Bayer$4K
- plus $1K from 11 others
Across 133 payments — averaging $3901.80 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Vertex$209K
- Mallinckrodt Enterprises LLC$102K
- Otsuka Pharmaceutical Co., Ltd.$88K
- Otsuka Pharmaceutical Development & Commercialization, Inc.$57K
- AstraZeneca$22K
- Calliditas Therapeutics US Inc.$22K
- plus $21K from 3 others
What the payments were for
- Consulting fees$98,92035%
- Speaking & faculty fees$156,91756%
- Travel & lodging$20,8197%
- Food & beverage$5,2492%
- Education$2010%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Mallinckrodt Hospital Products Inc. | 92 | $215,369 |
| Travere Therapeutics, Inc. | 20 | $19,910 |
| Otsuka America Pharmaceutical, Inc. | 25 | $19,062 |
| Calliditas Therapeutics US Inc. | 11 | $11,875 |
| Mallinckrodt Enterprises LLC | 15 | $10,651 |
| Bayer | 3 | $4,090 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 2 | $185 |
| Novartis | 2 | $176 |
| Aurinia Pharma U.S., Inc. | 2 | $148 |
| Vertex | 2 | $139 |
| GSK | 1 | $125 |
| Gilead | 1 | $125 |
| Amgen | 3 | $109 |
| Vifor Pharma, Inc. | 1 | $84 |
| Akebia Therapeutics Inc | 1 | $25 |
| Nxstage Medical, Inc. | 1 | $21 |
| Recordati_rare_diseases_inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$282,106 in reported general payments places this provider in the 95th percentile of 206 nephrology providers in Louisiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| LupkynisVoclosporin | 11 | $158,100 |
| JardianceEmpagliflozin | 41 | $44,599 |
| InvokanaCanagliflozin | 37 | $36,256 |
| FarxigaDapagliflozin Propanediol | 31 | $31,507 |
| VeltassaPatiromer Calcium Sorbitex | 25 | $29,385 |
| LokelmaSodium Zirconium Cyclosilicate | 15 | $14,423 |
| Potassium Citrate ErPotassium Citrate | 17 | $1,144 |
| Cinacalcet Hcl | 19 | $950 |
| Calcitriol | 34 | $641 |
| Chlorthalidone | 30 | $553 |
| Telmisartan | 11 | $525 |
| Tacrolimus | 12 | $504 |
| Irbesartan | 12 | $498 |
| Metoprolol Succinate | 21 | $403 |
| Valsartan | 23 | $367 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Aurinia Pharma U.S., Inc.Lupkynis | $148 | $158,10011 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 206 nephrology providers in Louisiana.
Other nephrology in New Orleans
- Michael TouchyNew Orleans$56K
- Juan MedauraNew Orleans$14K
- Farshid YazdiNew Orleans$14K
- Mihran NaljayanNew Orleans$10K
- Rhea BhargavaNew Orleans$9K
- April FoxNew Orleans$8K
- Myra KleinpeterNew Orleans$7K
- Joshua LowentrittNew Orleans$7K
- Angela ReginelliNew Orleans$6K
- Francisco CruzNew Orleans$6K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.